drugset / Trial / NCT01961271
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
Phase 4
Completed
114 enrolled
Mundipharma Pte Ltd.
Mundipharma (Hong Kong) Ltd · collabMundipharma Distribution GmBH (Philippine Branch) · collabMundipharma Korea Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, who are not adequately responding to non-opioid painkillers.
Timeline
- Start
- 2013-06
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 5 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 10 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 15 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 20 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 25 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 30 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 40 mg | Other |